On July 3, 2025 Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies, reported that Boehringer Ingelheim has selected a third drug candidate, which will now advance into IND-enabling studies under their ongoing collaboration (Press release, Oxford BioTherapeutics, JUL 3, 2025, View Source [SID1234656420]). The target, OB33, was identified using OBT’s proprietary OGAP-Verify discovery platform. As a result of this milestone, OBT will receive a payment from Boehringer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Immuno-oncological therapies have transformed the cancer treatment landscape. They are however only effective in a subset of patients, requiring the identification of novel immunotherapy targets. The collaboration with Oxford BioTherapeutics complements Boehringer Ingelheim’s development of next-generation potentially life-changing cancer immunotherapies with the identification of unique and specific cancer targets.
Dr. Christian Rohlff, Chief Executive Officer, said: "We are pleased to see our partnership with Boehringer Ingelheim reach an important preclinical milestone. It reflects the strength of our collaboration and the scientific excellence of our OGAP discovery platform. This achievement reinforces our strategy of partnering with world-class organizations to translate breakthrough science into potential new cancer therapies. We look forward to the next phase of this highly successful partnership and to continuing to work together to develop innovative first-in-class treatments for patients with difficult to treat cancers."
OBT’s recently launched enhanced OGAP-Verify discovery platform allows for enhanced sensitivity and target selection, addressing key challenges in the design of therapeutic antibodies and diagnostic tools. This has resulted in an increased overall success rate of these novel compounds transitioning into clinical development.
Under the multi-year collaboration, OBT has identified targets using the OGAP-Verify platform, while Boehringer is responsible for the development and commercialization of resulting product candidates.
The OBT–Boehringer partnership began in 2013 and has expanded through subsequent agreements in 2020 and 2022 to include additional programs. The collaboration has yielded multiple development-stage assets, with two candidates currently in clinical trials, one compound now in IND enabling studies, and a fourth target recently optioned by Boehringer Ingelheim.